Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
P/E ratio for Adial Pharmaceuticals, Inc. (ADIL)
P/E ratio as of 2023: -0.38
According to Adial Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.38. At the end of 2022 the company had a P/E ratio of -0.46.
P/E ratio history for Adial Pharmaceuticals, Inc. from 2015 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -0.38 |
| 2022 | -0.46 |
| 2021 | -2.58 |
| 2020 | -1.95 |
| 2019 | -2.76 |
| 2018 | -2.10 |
| 2017 | -19.46 |
| 2016 | -46.05 |
| 2015 | -23.68 |